[Prevention of venous XXXX by fondaparinux 2.5mg in general practice. ArchiMed Ville].

@entity1 @entity27408 @entity1211 @entity1031
OBJECTIVE: To evaluate the mean duration of treatment course with fondaparinux 2.5mg ( @entity27408 (  )) in the setting of ambulatory general medicine, with respect to its indication in thromboprophylaxis for medically ill @entity1 and to describe the population treated. METHODS: Observational, prospective, national, multicenter, pharmaco-epidemiological study, performed in France, at the request of the Transparency Commission (a division of the French Health Regulatory Authority). The general practitioners had to include the first three adult @entity1 , considered as @entity1 at high risk of venous @entity1031 and immobilized for acute medical illness, treated with initiation of thromboprophylaxis by fondaparinux 2.5mg. RESULTS: Two hundred and seventeen general practitioners included 840 @entity1 . The mean age of @entity1 was 63.6  18.1years, and 63% of @entity1 (n=520/831) were females. The real total administration duration of the treatment by fondaparinux 2.5mg was known for 797 @entity1 and was 15.8  12.4 days on average (range: 1-90days, median: 10days). In 40% of @entity1 , the duration ranged from 6 to 14days [duration consistent with the summary of product characteristics (SmPC)]. Among the 834 @entity1 analyzed, 569 (68%) suffered from at least one acute illness and had at least one risk factor for @entity1211 ( @entity1211 ). The indication did fully comply with the summary of product characteristics of fondaparinux 2.5mg in 52% of the @entity1 (n=434/834 @entity1 ). CONCLUSION: The results of the ArchiMed study support that the thromboprophylaxis treatment with fondaparinux 2.5mg in ambulatory general medicine, and the associated medical conditions were usually consistent with the SmPC or guidelines. However, a difference was found for the duration and the initial indication, in situations that may be regarded as presenting a risk by the prescriber.
